INTRODUCTION
Nitric oxide (NO) has been recognized as an intercellular messenger in the central nervous system (Bredt and Snyder, 1989) . Interestingly, withaferin A share have an anxiolytic-like effect, decrease motor activity, possess an anticonvulsant effect and decrease cyclic GMP content (Khan and Ghosh, 2010; Kulkarni and Dhir, 2008; Bhattacharya, 2002; Bredt and Snyder, 1989) . Therefore, we hypothesized that the brain nitrergic system may be involved in some of the effects of withaferin A. The aim of the present study was to elucidate whether the behavioural effects of an anxiolytic, withaferin A, could be modulated by the NO precursor L-arginine. Moreover, the effect of withaferin A on the brain NO synthase activity was measured in ex vivo.
MATERIALS AND METHODS

Animals
Male Wistar rats (150 to 200 g) were used in the study. Rats were housed at a constant temperature of 20±2°C under a 12 h light; *Corresponding author. E-mail: zavedkhan@vit.ac.in. Tel: (0416)2243091/93 Ext-2546. Fax-(0416) 2243092. 12 h dark cycle. The animals (n = 6 to 10 per group) had free access to food and water throughout the experiments. Animal care was as per Indian National Science Academy (INSA) Guidelines for the Care and Use of Animals in Scientific Research, and the study had the approval of Institutional Animal Ethical Committee (IAEC).
Stress procedure
The animals were subjected to restraint stress for 1 h at room temperature by immobilizing them in adjustable Plexiglas restrainers (INCO, Ambala). Immediately after the restraint stress procedure, the rats were exposed to the behavioral tests.
Elevated plus-maze test
The apparatus and procedure have been previously described (Volke et al., 1997) . 
Open field test
Immediately after the plus-maze test, the rats were placed singly into an open field (1 m×1 m, divided by lines into 16 equal squares) and observed in 4 min to measure locomotor activity. The number of line crossings and rearing were counted.
Rotarod
The rotarod performance was measured as described by Suzdak et al. (1992) . The rats were trained on the day before the test to stay on the rotating wooden bar (diameter 8 cm, speed 9 rpm) for at least 3 min. On the test day, the animals were put on the rotarod and the number of falls during a 3 min session was registered.
NO synthase assay
Brain NOx contents were determined as described by Tracey et al. (1995) . Brain samples were homogenized in 5 ml distilled water and centrifuged at 10 000×g for 15 min at 4°C. 50 µl of supernatant was mixed with 20 µl of 0.11 mM FAD and 20 mU of nitrate reductase. Samples were allowed to incubate for 1 h at room temperature in the dark. Then 5 µl of 1 M ZnSO4 was added to the samples in order to precipitate the proteins. Samples were centrifuged at 6000 ×g, for 5 min at 4°C and the supernatants were removed. 100 µl of Griess reagent (1:1 mixture of 1% sulphanilamide in 5% H3PO4 and 0.1% N-(1-naphthyl)-ethylenediamine) was added to 50 µl of supernatant and the mixture was incubated for 10 min at room temperature. Absorbance was measured at 540 nm in a microassay plate by microscan MS 5605A (Electronics Corporation of India) and converted to NOx content, using a nitrate standard curve. Brain supernatant protein was estimated by Lowry's method (Lowry et al., 1951) . The data were expressed as nmol NOx/mg protein.
Extraction of withaferin A and drugs
The roots of Withania somnifera grown in natural habitat and purchased from an authorized dealer were air-dried in shade and finely powdered. The chief botanist at Indian Agricultural Research Institute (IARI), New Delhi, India, identified the roots and a voucher specimen (accession number NISCAIR/RHM/F-3/2008/Consult/473) has been deposited at the herbarium of IARI. The root powder was exhaustively extracted with methanol:water (4:1, v/v) under reflux (WS). This extract was partitioned with chloroform and water to give WS-chloroform and WS-water, respectively. WS-chloroform was subjected to 12 successive elutions of water and acetonitrile (ACN) and these elutions were labeled from A1 to A12.
HPLC (Waters, Milford, U.S.A.) of W. somnifera extracts was performed using Kromasil C8 column (4.6 mm × 25 cm, 5 µm), and the mobile phase consisted of ACN and water (1:1, v/v) at a flow rate of 1 ml/min for a run time of 30 min. The HPLC of fractions was conducted using Novapak C18 column (3.9 mm × 15 cm, 4 µm) and the mobile phase consisted of potassium-dihydrogen orthophosphate (0.05 M) and ACN (3:7, v/v) at the flow rate of 1.5 ml/min for a run time of 30 min. The photodiode array (PDA) detector was set to detect at 229 nm and scan spectral data from 190 to 400 nm. Using the standard Withaferin A (Natural Remedies Private Ltd., Bangalore, India), the bioactive constituents of the extracts were quantified by external calibration method. The following drugs were used: L-Arginine and D-Arginine (Sigma Aldrich). All drugs were freshly prepared and given intraperitoneally (i.p.) in a volume of 0.1 ml/100 g body weight of rats at different time intervals before the testing.
Statistics
The data were analyzed using a one-way analysis of variance Khan and Ghosh 235 (ANOVA) followed by Dunnett's test for post hoc comparisons. A Pvalue of at least 0.05 was considered as the level of significance in all statistical tests.
RESULTS
Elevated-plus-maze and open field
The results are shown in Figures 1 and 2 Figure 1A ). ANOVA did not show any drug effect on the ambulation in Figure 1B (F = 1.25, P>0.1). L-Arginine seems to cause a true change in the anxiolytic-like action of withaferin A.
Rotarod performance
Treatment had significant effect on the motor coordination of rats on rotarod (F = 6.0, P<0.01). Withaferin A (40 mg/kg) increased the number of falls during the 3 min test session from 0.4±0.2 to 9.4±2.4 (P<0.01). Pretreatment with L-arginine (100) did not modify the motor in coordination caused by withaferin A (number of falls 8.4±1.9 and 9.6±1.9, respectively). There is no change in motor activity with treatment of both the drugs.
NO synthase activity
ANOVA revealed a significant drug effect on the brain NO synthase measured ex vivo (F = 60, P<0.0001 and F = 46, P<0.0001, respectively). The withaferin A (40 mg/kg i.p. 30 min prior sampling) decreased NO synthase activity by more than 65% (P<0.001) in cortex and 70% (P<0.001) in brain, as shown in Figure 3 . There is significant change in NO level with withaferin A and Larginine but not with D-arginine.
DISCUSSION
The main finding of the present study is that pretreatment with L-arginine, abolished the anxiolytic-like effect of withaferin A in the elevated plus-maze. L-Arginine seems to cause a true change in the anxiolytic-like action of withaferin A, since Faria et al. (1997) as well as our group (Volke et al., 1997) have shown that L-arginine, (60 and 100 mg/kg i.p., respectively) administered alone, does Afr. J. Pharm. Pharmacol. to account for the mentioned action. L-arginine (150 and 300 mg/kg i.p.) has been shown to increase brain NO synthesis by about 50% (Salter et al., 1996 showed that L-NOARG has an anxiogenic-like effect in the elevated plus-maze. We do not have any explanation for these discrepancies, but non-specific effects of the drug on locomotion cannot be ruled out. We are unable to assess whether an increase in NO synthesis affects the benzodiazepine induced hypolocomotion, because the dose of withaferin A used (10 mg/kg) did not significantly suppress the motor activity. L-Arginine did not modify the motor impairment caused by withaferin A (40 mg/kg), even though the dose of L-arginine was increased to 200 mg/kg, demonstrating that not all the effects of withaferin A are sensitive to an increase of the NO synthesis.
In another set of experiments, we tested the hypothesis that withaferin A may directly affect the NO synthase activity, which in turn would explain the behavioural effect of L-arginine. However, withaferin A did modify NO synthase activity as measured ex vivo, decreased activity by more than 60%. In conclusion, the present study indicates that the anxiolytic-like effect of withaferin A depends on the level of NO synthesis. However, withaferin A is an inhibitor of NO synthase, but may affect the NO synthase balance indirectly via some unknown mechanism which can be further investigated.
